CD40 and cancer: Bispecific antibodies (bsAbs) can simultaneously bind to two different targets, which can have the compound and synergistic effects in cancer immunotherapy.18 In our previous study,19 we designed an anti-CD40-scFv-linked anti-HER2 (CD40 ×HER2) bsAb that specifically agitates CD40 signaling and inhibits the dimerization of HER2.